Table 3. Base Case 1: Pairwise cost effectiveness analysis.
| Strategy | Costs | QALYs | Incremental costs | Incremental QALYs | ICER/ QALY gained |
|---|---|---|---|---|---|
| Standard pathway | £514,187 | 447.963 | |||
| Kardia Mobile | £515,551 | 449.249 | £1,364 | 1.286 | £1,060 |
| imPulse | £530,745 | 448.987 | £16,557 | 1.024 | £16,165 |
| MyDiagnostick | £521,233 | 449.024 | £7,046 | 1.061 | £6,638 |
| Generic lead-I device | £516,730 | 449.246 | £2,543 | 1.284 | £1,981 |
| Zenicor-ECG | £518,468 | 449.199 | £4,281 | 1.236 | £3,462 |
| RhythmPad GP* | £518,436 | 448.573 | £4,249 | 0.610 | £6,962 |
ICER = incremental cost effectiveness ratio; QALY = quality adjusted life year
*Algorithm interpretation